54
|
de Koning PD, Gladwell IR, Moses IB, Panesar MS, Pettman AJ, Thomson NM. Development of an Enabling Route to PF-00610355: A Novel Inhaled β2-Adrenoreceptor Agonist. Org Process Res Dev 2011. [DOI: 10.1021/op2001904] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Pieter D. de Koning
- Research API, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
| | - Iain R. Gladwell
- Research API, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
| | - Ian B. Moses
- Research API, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
| | - Maninder S. Panesar
- Research API, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
| | - Alan J. Pettman
- Research API, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
| | - Nicholas M. Thomson
- Research API, Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
| |
Collapse
|
61
|
Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010; 11:149. [PMID: 21034447 PMCID: PMC2991288 DOI: 10.1186/1465-9921-11-149] [Citation(s) in RCA: 87] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2010] [Accepted: 10/29/2010] [Indexed: 02/08/2023] Open
Abstract
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long-acting bronchodilators are the mainstay of therapy; as symptoms progress, guidelines recommend combining bronchodilators from different classes to improve efficacy. Inhaled long-acting β2-agonists (LABAs) have been licensed for the treatment of COPD since the late 1990s and include formoterol and salmeterol. They improve lung function, symptoms of breathlessness and exercise limitation, health-related quality of life, and may reduce the rate of exacerbations, although not all patients achieve clinically meaningful improvements in symptoms or health related quality of life. In addition, LABAs have an acceptable safety profile, and are not associated with an increased risk of respiratory mortality, although adverse effects such as palpitations and tremor may limit the dose that can be tolerated. Formoterol and salmeterol have 12-hour durations of action; however, sustained bronchodilation is desirable in COPD. A LABA with a 24-hour duration of action could provide improvements in efficacy, compared with twice-daily LABAs, and the once-daily dosing regimen could help improve compliance. It is also desirable that a new LABA should demonstrate fast onset of action, and a safety profile at least comparable to existing LABAs.A number of novel LABAs with once-daily profiles are in development which may be judged against these criteria. Indacaterol, a LABA with a 24-hour duration of bronchodilation and fast onset of action, is the most advanced of these. Preliminary results from large clinical trials suggest indacaterol improves lung function compared with placebo and other long-acting bronchodilators. Other LABAs with a 24-hour duration of bronchodilation include carmoterol, vilanterol trifenatate and oldaterol, with early results indicating potential for once-daily dosing in humans.The introduction of once-daily LABAs also provides the opportunity to develop combination inhalers of two or more classes of once-daily long-acting bronchodilators, which may be advantageous for COPD patients through simplification of treatment regimens as well as improvements in efficacy. Once-daily LABAs used both alone and in combination with long-acting muscarinic antagonists represent a promising advance in the treatment of COPD, and are likely to further improve outcomes for patients.
Collapse
Affiliation(s)
- Donald P Tashkin
- David Geffen School of Medicine, Division of Pulmonary and Critical Care Medicine, UCLA, Los Angeles, California, USA
| | - Leonardo M Fabbri
- Department of Respiratory Diseases, University of Modena & Reggio Emilia, Via del Pozzo 71, I-41124 Modena, Italy
| |
Collapse
|
65
|
Baur F, Beattie D, Beer D, Bentley D, Bradley M, Bruce I, Charlton SJ, Cuenoud B, Ernst R, Fairhurst RA, Faller B, Farr D, Keller T, Fozard JR, Fullerton J, Garman S, Hatto J, Hayden C, He H, Howes C, Janus D, Jiang Z, Lewis C, Loeuillet-Ritzler F, Moser H, Reilly J, Steward A, Sykes D, Tedaldi L, Trifilieff A, Tweed M, Watson S, Wissler E, Wyss D. The Identification of Indacaterol as an Ultralong-Acting Inhaled β2-Adrenoceptor Agonist. J Med Chem 2010; 53:3675-84. [PMID: 20402514 DOI: 10.1021/jm100068m] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- François Baur
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - David Beattie
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - David Beer
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - David Bentley
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Michelle Bradley
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Ian Bruce
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Steven J. Charlton
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Bernard Cuenoud
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Roland Ernst
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Robin A. Fairhurst
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Bernard Faller
- Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, Novartis Campus, CH-4056 Basel, Switzerland
| | - David Farr
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Thomas Keller
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - John R. Fozard
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Joe Fullerton
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Sheila Garman
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Julia Hatto
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Claire Hayden
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Handan He
- DMPK-Translational Science, Novartis Institutes for Biomedical Research, One Health Plaza, East Hanover, New Jersey
| | - Colin Howes
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Diana Janus
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Zhengjin Jiang
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Christine Lewis
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Frederique Loeuillet-Ritzler
- Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, Novartis Campus, CH-4056 Basel, Switzerland
| | - Heinz Moser
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - John Reilly
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Alan Steward
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - David Sykes
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Lauren Tedaldi
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Alexandre Trifilieff
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Morris Tweed
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Simon Watson
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Elke Wissler
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| | - Daniel Wyss
- Respiratory Diseases Area, Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K. and Lichtstrasse, CH-4056 Basel, Switzerland
| |
Collapse
|